

## SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with  
Kallikrein 12 (KLK12)

<130> BHC 04 01 018

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 1074

<212> DNA

<213> Homo sapiens

<400> 1

gcaggttagt ggacggagag atagcagcga cgaggacagg ccaaacagt acagccacgt	60
agaggatctg gcagacaaag agacaaggtg agaaggagac ttggaaagt acccaccoatg	120
gggctcagca tcttttgct cctgtgtgtt ctgggctca gccaggcagc cacaccgaag	180
atttcaatg gcactgagtg tgccgttaac tcacagccgt ggcaggtggg gctgttttag	240
ggcaccagcc tgcgctgcgg ggggttcattt attgaccaca ggtgggtctt cacagcggt	300
cactgcagcg gcagcaggta ctgggtgcgc ctggggaaac acagcctcag ccagctcgac	360
tggaccgagc agatccggca cagcggttc tctgtgaccc atcccgcta cctggagcc	420
tcgacgagcc acgagcacga cctccggctg ctgcggctgc gcctgcccgt ccgcgttaacc	480
agcagcggttc aaccctgcc cctgccaat gactgtcaa ccgctggcac cgagtgcac	540
gtctcaggct ggggcattcac caaccaccca cggAACCCAT tcccgatct gctccagtgc	600
ctcaacctct ccattcgatcc ccatgccacc tgccatggtg tgtatccgg gagaatcagc	660
agcaacatgg tgtgtgcagg cggcgccccg gggcaggatg cctgcccagg tgattctgg	720
ggcccccctgg tgtgtgggg agtccttcaa ggtctgggtt cctgggggtc tgtggggccc	780
tgtggacaag atggcatccc tggagtctac accttatattt gcaagtatgt ggactggatc	840
cggatgatca tgaggaacaa ctgacctgtt tcctccaccc ccaccccccac cccttaactt	900
gggtacccct ctggccctca gagcaccaat atctcctcca tcacttcccc tagctccact	960
cttggggcc tggaaacttc ttggaaacttt aactcctgcc agcccttcta agacccacga	1020
gcggggtagag agaagtgtgc aatagtctgg aataaatata aatgaaggag gggc	1074

<210> 2

<211> 248

<212> PRT

<213> Homo sapiens

<400> 2

- 2 -

Met Gly Leu Ser Ile Phe Leu Leu Leu Cys Val Leu Gly Leu Ser Gln  
 1 5 10 15  
 Ala Ala Thr Pro Lys Ile Phe Asn Gly Thr Glu Cys Gly Arg Asn Ser  
 20 25 30  
 Gln Pro Trp Gln Val Gly Leu Phe Glu Gly Thr Ser Leu Arg Cys Gly  
 35 40 45  
 Gly Val Leu Ile Asp His Arg Trp Val Leu Thr Ala Ala His Cys Ser  
 50 55 60  
 Gly Ser Arg Tyr Trp Val Arg Leu Gly Glu His Ser Leu Ser Gln Leu  
 65 70 75 80  
 Asp Trp Thr Glu Gln Ile Arg His Ser Gly Phe Ser Val Thr His Pro  
 85 90 95  
 Gly Tyr Leu Gly Ala Ser Thr Ser His Glu His Asp Leu Arg Leu Leu  
 100 105 110  
 Arg Leu Arg Leu Pro Val Arg Val Thr Ser Ser Val Gln Pro Leu Pro  
 115 120 125  
 Leu Pro Asn Asp Cys Ala Thr Ala Gly Thr Glu Cys His Val Ser Gly  
 130 135 140  
 Trp Gly Ile Thr Asn His Pro Arg Asn Pro Phe Pro Asp Leu Leu Gln  
 145 150 155 160  
 Cys Leu Asn Leu Ser Ile Val Ser His Ala Thr Cys His Gly Val Tyr  
 165 170 175  
 Pro Gly Arg Ile Thr Ser Asn Met Val Cys Ala Gly Gly Val Pro Gly  
 180 185 190  
 Gln Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Gly  
 195 200 205  
 Val Leu Gln Gly Leu Val Ser Trp Gly Ser Val Gly Pro Cys Gly Gln  
 210 215 220  
 Asp Gly Ile Pro Gly Val Tyr Thr Tyr Ile Cys Lys Tyr Val Asp Trp  
 225 230 235 240  
 Ile Arg Met Ile Met Arg Asn Asn  
 245

<210> 3  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> forward primer

<400> 3  
 ctcttgttgg cctggaaact

<210> 4

<211> 19  
<212> DNA  
<213> artificial sequence

<220>  
<223> reverse primer

<400> 4  
**ccgctcggtgg gtcttagaa**

19

<210> 5  
<211> 25  
<212> DNA  
<213> artificial sequence

<220>  
<223> probe

<400> 5  
**cttggaaactt taactcctgc cagcc**

25